142 related articles for article (PubMed ID: 31937861)
1. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment.
Serda M; Malarz K; Mrozek-Wilczkiewicz A; Wojtyniak M; Musioł R; Curley SA
Sci Rep; 2020 Jan; 10(1):260. PubMed ID: 31937861
[TBL] [Abstract][Full Text] [Related]
2. Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.
Malarz K; Korzuch J; Marforio TD; Balin K; Calvaresi M; Mrozek-Wilczkiewicz A; Musiol R; Serda M
Int J Nanomedicine; 2023; 18():1709-1724. PubMed ID: 37025922
[TBL] [Abstract][Full Text] [Related]
3. Fyn kinase in brain diseases and cancer: the search for inhibitors.
Schenone S; Brullo C; Musumeci F; Biava M; Falchi F; Botta M
Curr Med Chem; 2011; 18(19):2921-42. PubMed ID: 21651487
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
[TBL] [Abstract][Full Text] [Related]
5. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
8. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
9. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
11. A Fast and Clean BTK Inhibitor.
Gabizon R; London N
J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.
Je DW; O YM; Ji YG; Cho Y; Lee DH
Pancreas; 2014 Jul; 43(5):768-76. PubMed ID: 24763074
[TBL] [Abstract][Full Text] [Related]
13. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
[TBL] [Abstract][Full Text] [Related]
14. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
15. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
[TBL] [Abstract][Full Text] [Related]
18. A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies.
Irwin ME; Johnson BP; Manshouri R; Amin HM; Chandra J
Oncotarget; 2015 Sep; 6(27):23631-46. PubMed ID: 26136341
[TBL] [Abstract][Full Text] [Related]
19. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
20. Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.
Poli G; Lapillo M; Granchi C; Caciolla J; Mouawad N; Caligiuri I; Rizzolio F; Langer T; Minutolo F; Tuccinardi T
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):956-961. PubMed ID: 29747534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]